{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:40Z","timestamp":1791924760842,"version":"4.3.4"},"reference-count":56,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition with a substantial impact on patients, particularly due to ocular involvement known as atopic keratoconjunctivitis (AKC). Current therapeutic approaches, such as dupilumab, often lead to conjunctivitis, prompting exploration of alternative treatments like upadacitinib. Methods: We collected dermatological and ophthalmological prospective clinical evaluations of six adults with moderate-to-severe AD, undergoing treatment with upadacitinib after discontinuation of dupilumab due to the onset of AKC during therapy and the worsening of dermatitis in particular in the head and neck region. Clinical evaluations, including EASI scores, itch and sleep NRS, DLQI, and ocular parameters, were performed at baseline (during screening assessment before switching to upadacitinib) and then at week 12 and week 24. Clinical evaluation of AKC was performed by a team of ophthalmologists. Results: Upadacitinib not only improved atopic dermatitis in terms of EASI, itching, and sleep NRS, but also demonstrated a notable reduction in ocular signs and symptoms, as indicated by the Visual Analogue Scale (VAS), the Efron scale, and the Ocular Surface Disease Index Symptom Severity (OSDISS) scores. Discussion: Our observation of common clinical practice underscores the substantial impact of biological and small-molecule therapies on AD, emphasizing the limitation posed by dupilumab-associated conjunctivitis. Switching to upadacitinib significantly improved both clinical and functional ocular outcomes, suggesting its potential as an alternative therapeutic option for AD patients with ocular involvement. Conclusion: The presented data provides insights into the complex interplay between systemic therapies and ocular manifestations in AD. Upadacitinib emerges as a promising option to address dupilumab-associated conjunctivitis, offering improved quality of life for patients.<\/jats:p>","DOI":"10.3390\/jcm13133818","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:06:07Z","timestamp":1719824767000},"page":"3818","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice"],"prefix":"10.3390","volume":"13","author":[{"given":"Claudia","family":"Paganini","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-5741","authenticated-orcid":false,"given":"Sara","family":"Spelta","sequence":"additional","affiliation":[{"name":"Ophthalmology Complex Operative Unit, University Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1286-9507","authenticated-orcid":false,"given":"Lorenzo","family":"Tofani","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3070-4071","authenticated-orcid":false,"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-6896","authenticated-orcid":false,"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"},{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Coassin","sequence":"additional","affiliation":[{"name":"Ophthalmology Complex Operative Unit, University Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Zazzo","sequence":"additional","affiliation":[{"name":"Ophthalmology Complex Operative Unit, University Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5175","authenticated-orcid":false,"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"},{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"adv00160","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and Incidence of Atopic Dermatitis: A Systematic Review","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"354250","DOI":"10.1155\/2014\/354250","article-title":"Atopic dermatitis: Natural history, diagnosis, and treatment","volume":"2014","author":"Thomsen","year":"2014","journal-title":"ISRN Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaad.2003.08.003","article-title":"Guidelines of care for atopic dermatitis","volume":"50","author":"Hanifin","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"adv00264","DOI":"10.2340\/00015555-3629","article-title":"Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process","volume":"100","author":"Thyssen","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1067\/mjd.2002.122736","article-title":"Eyelid dermatitis: Experience in 203 cases","volume":"47","author":"Guin","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaad.2013.10.036","article-title":"Atopic keratoconjunctivitis: A review","volume":"70","author":"Chen","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/1203475417743233","article-title":"Diagnosis and Management of Conjunctivitis for the Dermatologist","volume":"22","author":"Gooderham","year":"2018","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(03)02539-8","article-title":"Consensus Conference on Pediatric Atopic Dermatitis","volume":"49","author":"Eichenfield","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/ACI.0b013e32833e16e4","article-title":"Atopic keratoconjunctivitis and atopic dermatitis","volume":"10","author":"Guglielmetti","year":"2010","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.alit.2020.03.005","article-title":"Japanese guidelines for allergic conjunctival diseases 2020","volume":"69","author":"Miyazaki","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4274\/tjo.galenos.2020.11456","article-title":"Current Knowledge in Allergic Conjunctivitis","volume":"51","author":"Villegas","year":"2021","journal-title":"Turk. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.20510\/pbj\/9\/i3\/1364","article-title":"Integrating Recommendations to Improve Treatment Outcomes in the Clinical Management of Allergic Conjunctivitis","volume":"9","author":"Bharali","year":"2021","journal-title":"Pharm. Biosci. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.eye.6700675","article-title":"Vernal keratoconjunctivitis","volume":"18","author":"Bonini","year":"2004","journal-title":"Eye"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.iac.2010.06.004","article-title":"Atopic dermatitis and keratoconjunctivitis","volume":"30","author":"Bielory","year":"2010","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2020.09.046","article-title":"Recognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis","volume":"85","author":"Cheng","year":"2021","journal-title":"J Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0002-9394(53)92176-X","article-title":"Atopic keratoconjunctivitis","volume":"36","author":"Hogan","year":"1953","journal-title":"Am. J. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1111\/jdv.17210","article-title":"Dupilumab and conjunctivitis: A case series of twenty patients","volume":"35","author":"Calabrese","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.alit.2022.07.005","article-title":"Executive summary: Japanese guidelines for allergic conjunctival diseases 2021","volume":"71","author":"Miyazaki","year":"2022","journal-title":"Allergol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40257-019-00455-5","article-title":"Ocular Co-Morbidities of Atopic Dermatitis. Part I: Associated Ocular Diseases","volume":"20","author":"Beck","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajo.2004.07.044","article-title":"Unilateral keratoconus in a child with chronic and persistent eye rubbing","volume":"139","author":"Ioannidis","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.18240\/ijo.2019.11.17","article-title":"The correlation between keratoconus and eye rubbing: A review","volume":"12","author":"Najmi","year":"2019","journal-title":"Int. J. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00417-021-05081-8","article-title":"Eye rubbing in the aetiology of keratoconus: A systematic review and meta-analysis","volume":"259","author":"Sahebjada","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00347-024-01984-z","article-title":"Aktuelles zur Keratoconjunctivitis vernalis und atopica [Current aspects of vernal and atopic keratoconjunctivitis]","volume":"121","author":"Messmer","year":"2024","journal-title":"Ophthalmologie"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/aos.14509","article-title":"Association between atopic keratoconjunctivitis and the risk of keratoconus","volume":"99","author":"Weng","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/14712598.2017.1387245","article-title":"Dupilumab for the treatment of asthma","volume":"17","author":"Pelaia","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: Phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Parmentier, J.M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H.S., Padley, R.J., George, J.S., and Hyland, D. (2018). In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol., 2.","DOI":"10.1186\/s41927-018-0031-x"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ncprheum0631","article-title":"Primer: Signal transduction in rheumatic disease--a clinician\u2019s guide","volume":"3","author":"Sweeney","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.17981","article-title":"Dupilumab ocular side effects in patients with atopic dermatitis: A systematic review","volume":"36","author":"Neagu","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2021.09.029","article-title":"Dupilumab-induced ocular surface disease: A systematic review","volume":"86","author":"Fachler","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e15575","DOI":"10.1111\/dth.15575","article-title":"Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis","volume":"35","author":"Hayama","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/derm.2022.0063","article-title":"Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience","volume":"34","author":"Gelato","year":"2023","journal-title":"Dermatitis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100042","DOI":"10.1016\/j.xjidi.2021.100042","article-title":"A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis","volume":"1","author":"Kamata","year":"2021","journal-title":"JID Innov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40257-021-00646-z","article-title":"Dupilumab Facial Redness\/Dupilumab Facial Dermatitis: A Guide for Clinicians","volume":"23","author":"Muzumdar","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1002\/ski2.354","article-title":"Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report","volume":"4","author":"Galluzzo","year":"2024","journal-title":"Ski. Health Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/ajd.13924","article-title":"Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting","volume":"63","author":"Foley","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_46","first-page":"607","article-title":"Atopic Keratoconjunctivitis: Pathophysiology, Clinic, and Potential New Therapeutic Concepts","volume":"241","author":"Lapp","year":"2024","journal-title":"Klin. Monatsblatter Augenheilkd."},{"key":"ref_47","unstructured":"Ministero Della Salute (2023, March 03). Attivit\u00e0 dei Comitati Etici Istituiti ai Sensi del Decreto Ministeriale 18 Marzo 1998, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/0\/Cir_Min_2_Settembre_2002_CE.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13601-020-00349-4","article-title":"Validation of the DECA criteria for allergic conjunctivitis severity and control","volume":"10","author":"Navarro","year":"2020","journal-title":"Clin. Transl. Allergy."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"ESPRINT Study Group and Investigators, Valero, A., Alonso, J., Antepara, I., Bar\u00f3, E., Colas, C., del Cuvillo, A., Ferrer, M., Herdman, M., and Mart\u00ed-Guada\u00f1o, E. (2007). Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: The ESPRINT questionnaire. Value Health, 10, 466\u2013477.","DOI":"10.1111\/j.1524-4733.2007.00202.x"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/S0161-6420(91)32154-7","article-title":"Immunopathology of atopic keratoconjunctivitis","volume":"98","author":"Foster","year":"1991","journal-title":"Ophthalmology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00417-006-0285-7","article-title":"Th1-and Th2-type cytokines in chronic ocular allergy","volume":"244","author":"Leonardi","year":"2006","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Licata, G., Tancredi, V., Pezzolo, E., Pertusi, G., Tolino, E., Arisi, M., and Gambardella, A. (J. Eur. Acad. Dermatol. Venereol., 2023). Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: A case series, J. Eur. Acad. Dermatol. Venereol., ahead of print.","DOI":"10.1111\/jdv.19108"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/exd.14859","article-title":"Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis","volume":"32","author":"Chiricozzi","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/all.16045","article-title":"Dupilumab-associated ocular surface disease is characterized by a shift from Th2\/Th17 toward Th1\/Th17 inflammation","volume":"79","author":"Thormann","year":"2024","journal-title":"Allergy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/jdv.18922","article-title":"Expert consensus on the systemic treatment of atopic dermatitis in special populations","volume":"37","author":"Adam","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3818\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:30Z","timestamp":1760108850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":56,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13133818"],"URL":"https:\/\/doi.org\/10.3390\/jcm13133818","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}